Post-Myocardial Infarction Remodeling Prevention Therapy

Inclusion Criteria:

- MI within the past 10 days

- Peak CPK greater than 3000 Units/Litre (U/L) at time of MI, or a troponin T (TnT)
greater than 10 micrograms/Litre (mcg/L)

- At least 18 years old

- Willing to comply with the protocol

Exclusion Criteria:

- Documented MI greater than 10 days

- Chronic renal disease, as defined by estimated glomerular filtration rate (eGFR) less
than 30 milliliters/minute/1.73 square meter

- Life expectancy less than 18 months, as determined by a physician

- Existing pacemaker, Implantable Cardioverter Defibrillator (ICD), or Cardiac
Resynchronization Therapy (CRT) device

- QRS duration greater than 120 milliseconds (ms)

- Coronary Artery Bypass Graft (CABG) within 30 days prior to MI, or CABG procedure
planned

- Third degree atrioventricular (AV) block or symptomatic bradyarrhythmia

- Persistent atrial fibrillation (AF) that is not self terminating within 7 days or is
terminated electrically or pharmacologically

- Permanent AF that is non self terminating, with cardioversion failed or not attempted
within the past year

- NYHA Class IV

- Non-ischemic cardiomyopathy

- Pregnant or planning to become pregnant during the study

- Enrolled or planning to participate in a concurrent drug and/or device study during
the course of this clinical trial. Co-enrollment in concurrent trials is only allowed
with documented pre-approval from Medtronic, documenting that there is not a concern
that co-enrollment could confound the results of this trial.

- Breast feeding

- Of a vulnerable population as determined by local law or requirement, or a physician